30 Participants Needed

Calmer Therapy Bed for Premature Infants

MR
EA
NR
LR
Overseen ByLindsay Richter, MSc
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the Calmer therapy bed to determine if it aids premature infants' growth and development in the NICU. Calmer mimics skin-to-skin contact by providing a soothing surface, heartbeat sounds, and breathing motions tailored to each baby using their parents' recordings. The trial will compare the growth and brain activity of babies using Calmer for a few hours daily over 2-3 weeks with those receiving regular NICU care. Eligible participants are preterm infants born at 26-30 weeks who are on breathing support and have at least one English-speaking parent for consent. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could improve care for premature infants.

Will I have to stop taking my current medications?

The trial information does not specify whether participants must stop taking their current medications. It focuses on preterm infants in the NICU and does not mention any medication changes.

What prior data suggests that the Calmer therapy bed is safe for preterm infants?

Research has shown that the Calmer therapy bed is safe for premature babies. In a study with 58 preterm infants, Calmer reduced stress and maintained steady brain blood flow, similar to the usual care method known as facilitated tucking. Babies safely used Calmer for up to 6 hours a day.

Another study found that babies using Calmer maintained normal oxygen levels in their brains, comparable to those who received human touch. This indicates that Calmer does not harm critical functions like brain oxygen levels.

These findings suggest that Calmer is well-tolerated and does not harm babies. Both parents and hospital staff felt comfortable using Calmer, which supports its safety in hospitals.12345

Why are researchers excited about this trial?

The Calmer therapy bed for premature infants is unique because it offers a gentle, non-invasive way to support the development of preemies in a neonatal intensive care unit (NICU) setting. Unlike traditional incubator care, which primarily focuses on maintaining a stable environment, Calmer provides targeted therapy directly within the incubator for at least 3 hours a day. Researchers are excited about this approach because it could enhance the sensory environment for premature infants, potentially promoting better growth and neurological development during those critical early weeks.

What evidence suggests that the Calmer therapy bed is effective for reducing stress in preterm infants?

In this trial, some participants will receive the Calmer therapy, which previous studies have shown to reduce stress in premature babies during routine procedures. It stabilized their heart rates and ensured normal blood flow to the brain, similar to the benefits of human touch. Calmer mimics skin-to-skin care by providing a gentle heartbeat sound and breathing motion customized for each baby. Premature babies using Calmer maintained normal oxygen levels in their brains, crucial for healthy brain development. While more research is needed to understand the long-term effects, early findings suggest that Calmer could support growth and brain development in premature babies.12345

Who Is on the Research Team?

LH

Liisa Holsti, PhD

Principal Investigator

The University of British Columbia

MR

Manon Ranger, PhD

Principal Investigator

The University of British Columbia

Are You a Good Fit for This Trial?

This trial is for preterm infants in the NICU at BC Women's Hospital, born between 26-30 weeks gestational age. They can be on airway support but must not have major health issues like congenital anomalies, infections at enrolment, neurological injuries, cardiovascular instability or a history of maternal substance abuse.

Inclusion Criteria

My preterm baby was admitted to NICU at BC Women's Hospital, born at 26-30 weeks.
Infants who are on continuous positive airway pressure or are ventilated
My parent or caregiver can speak enough English to give consent.

Exclusion Criteria

My infant has had a serious brain injury like lack of oxygen, bleeding, or stroke.
My baby was born small, has birth defects, or was exposed to drugs in the womb.
My baby was born after 30 weeks of pregnancy.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Infants receive either Calmer therapy or standard NICU care for 2-3 weeks

2-3 weeks
Daily monitoring in NICU

Follow-up

Participants are monitored for growth and brain development outcomes after treatment

4 weeks

Extension

Potential continuation of monitoring for long-term outcomes in a larger RCT

Long-term

What Are the Treatments Tested in This Trial?

Interventions

  • Calmer
Trial Overview The study tests Calmer—a therapy bed designed to reduce stress and promote growth in preterm babies by mimicking skin-to-skin contact with artificial touch, heartbeat sounds and breathing motion. The trial compares daily use of Calmer for three weeks against standard NICU care to see if it improves physical growth and brain oxygen signaling.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: CalmerExperimental Treatment1 Intervention
Group II: ControlActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of British Columbia

Lead Sponsor

Trials
1,506
Recruited
2,528,000+

Women's Health Research Institute of British Columbia

Collaborator

Trials
8
Recruited
16,600+

Published Research Related to This Trial

The study evaluated the feasibility of a longitudinal study on sleep patterns and psychosocial health in parents of preterm and full-born infants, successfully recruiting 78 parents of full-born infants but facing challenges with only 25 parents of preterm infants.
Despite the feasibility of using actigraphs and sleep diaries for data collection, high attrition rates were noted, particularly at 6 and 12 months, indicating a need for improved recruitment strategies for parents of preterm infants.
Sleep patterns and psychosocial health of parents of preterm and full-born infants: a prospective, comparative, longitudinal feasibility study.Marthinsen, GN., Helseth, S., Småstuen, M., et al.[2022]
In a study of 13 premature infants, reducing sensory and environmental stimuli in the neonatal unit significantly increased their total sleep time, with infants averaging 696.4 minutes of sleep without management compared to 168.5 minutes with management.
The results showed that infants slept about 70.2% of the time during periods without intervention, compared to only 58.0% during periods with environmental management, indicating that a calmer environment is beneficial for premature infants' sleep.
[Effect of reducing sensory and environmental stimuli during hospitalized premature infant sleep].Orsi, KC., Llaguno, NS., Avelar, AF., et al.[2016]
A study involving 49 preterm infants tested the Calmer robotic device, which simulates skin-to-skin contact, to see if it could reduce pain during a blood test.
The results showed that Calmer was as effective as human touch-based treatment (facilitated tucking) in mitigating pain, but further research is needed to explore its long-term effects on stress reduction in preterm infants.
Calmer: a robot for managing acute pain effectively in preterm infants in the neonatal intensive care unit.Holsti, L., MacLean, K., Oberlander, T., et al.[2022]

Citations

Calmer: a robot for managing acute pain effectively in ...The purpose of this randomized controlled trial was to evaluate the efficacy of Calmer to reduce biobehavioral acute pain indices in stable preterm infants in ...
Creating a Calmer NICU: Optimizing Growth and Brain ...The 1st randomized controlled trial (RCT) in 58 preterm babies showed that during a routine blood test: Calmer lowered infant behavioral and heart stress ...
Cerebral hemodynamic response to a therapeutic bed for...Conclusions: Infants on Calmer maintained normal regional cerebral oxygen levels (55%–85%) no differently from infants receiving a human touch intervention ...
Cerebral hemodynamic response to a therapeutic bed for ...Preterm infants on Calmer maintained normal regional cerebral oxygen levels (55%–85%) no differently from infants receiving a human touch intervention ...
(PDF) Calmer: a robot for managing acute pain effectively ...More research is needed to determine effects of Calmer for stress reduction in preterm infants in the neonatal intensive care unit over longer periods. ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security